A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight Loss

ClinicalTrials.gov ID: NCT07663630

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07663630. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

AN INTERVENTIONAL, PHASE 1B, DOUBLE-BLIND, RANDOMIZED, SPONSOR-OPEN, 2-ARM STUDY TO INVESTIGATE THE EFFECT OF PONSEGROMAB ON SKELETAL MUSCLE MASS AND PHYSICAL FUNCTION IN ADULT PARTICIPANTS WITH NON-SMALL CELL LUNG CANCER ASSOCIATED CACHEXIA

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Study to investigate the effect of ponsegromab on skeletal muscle mass and physical function in adult participants with non-small cell lung cancer associated cachexia.

Study identification

NCT ID: NCT07663630
Recruitment status: Not yet recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Pfizer; Industry
Enrollment: 80 participants

Conditions and interventions

Conditions

Interventions

ponsegromab Drug
placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 23, 2026 (Estimated)
Primary completion: May 6, 2028 (Estimated)
Completion: Jul 1, 2029 (Estimated)
Last update posted: Sep 25, 2026

2026 – 2029

United States locations

U.S. sites: 6
U.S. states: 2
U.S. cities: 4

Facility	City	State	ZIP	Site status
Cancer Care Specialists of Illinois-Decatur	Decatur	Illinois	62526	—
Decatur Memorial Hospital	Decatur	Illinois	62526	—
Cancer Care Specialists of Illinois - Cancer Care Center of O'Fallon	O'Fallon	Illinois	62269	—
Dallas Cancer Specialists	Garland	Texas	75042	—
Houston Cancer Treatment Centers	Houston	Texas	77089	—
Lumi Research	Houston	Texas	77090	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07663630, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 25, 2026 · Synced Nov 13, 2026